Science Background
Innovative Anti-CD39 Tumor Therapeutics Targeting Tumor Microcirculation – Pan-Tumor Treatment
- CD39 is the key ectoenzyme controlling the initial steps in the conversion of extracellular ATP/ADP to adenosine to maintain homeostasis. In tumors, CD39 expression is dramatically elevated on vascular endothelial cells (EC) and immune cells – making CD39 a tumor attractive target
- ATP and adenosine – the conversion from ATP to adenosine being tightly controlled by the CD39 enzymatic activity – can serve as extracellular signaling molecules which exert opposite effects. In general, ATP is pro-inflammatory and has direct and indirect antitumor activities, whereas adenosine can act as immunosuppressant in the tumor and promote tumor growth
- Efforts in clinical studies to block the enzymatic activity of CD39 with both small molecules and antibodies have produced disappointing results with efficacy as a monotherapy agent in question for those drug agents
- By elucidating a role for tumor targeting with CD39 that is distinct from the enzymatic activity of the target, Purinomia has been able to develop drug candidates that are mechanistically distinct and with potencies required for both monotherapy and combination therapy uses
Leading Product
PUR001
PUR001’s Innovative Antitumor Activity Differentiate from Other CD39-targeted Drugs, which includes a mechanism-of-action resulting in massive tumor necrosis and immunogenic cell death, leading to increased activation of antitumor immune responses.
Unlike all of the other clinical anti-CD39 antibodies, PUR001 uniquely offers the opportunity to have monotherapy efficacy, as well as synergism with other I/O agents and with chemotherapies.
Clinical Development
Global Clinical Operation
Collaborated with global strategic partners,
Purinomia expanded its clinical operation to different regions beyond US market.
Strategic Pipeline
Purinomia has a robust, proprietary pipeline that is strategically designed to target high unmet needs – oncology and inflammatory diseases.